Core Viewpoint - Beijing Fuyuan Pharmaceutical Co., Ltd. announced that its wholly-owned subsidiary, Zhejiang Aisheng Pharmaceutical Co., Ltd., has received a drug registration certificate from the National Medical Products Administration for Dydrogesterone Tablets, which will enhance the company's product line and market competitiveness [1][4]. Drug Registration Certificate Details - The drug registration certificate for Dydrogesterone Tablets (10mg) was issued by the National Medical Products Administration, indicating that the drug has passed the consistency evaluation as per national policies [1]. Drug Information - Dydrogesterone is an orally absorbable synthetic progestogen, originally developed by Solvay Pharmaceuticals and approved for market in Portugal in July 1961. It was approved for sale in China in December 2002 for treating endogenous progesterone deficiency and supporting luteal function in assisted reproductive technology [1][2]. R&D Investment - As of the announcement date, Zhejiang Aisheng has invested a total of RMB 5.3716 million (approximately 0.537 million) in the research and development of this drug [2]. Market Status of Similar Drugs - According to data from Minai Network, the sales revenue of Dydrogesterone Tablets in China's three major terminal markets is approximately RMB 2.57 billion (approximately 25.70 million), with public hospitals accounting for RMB 2.20 billion (approximately 22.01 million), community health centers and township hospitals for RMB 61 million (approximately 0.61 million), and retail pharmacies and online pharmacies for RMB 308 million (approximately 3.08 million) [3].
北京福元医药股份有限公司 关于地屈孕酮片获得药品注册证书的公告